Physician profile
Michael J Morris
NPI 1861482416
$77,857.93
in general payments reported to CMS, 2019-2025
15 companies · $232 in 2025
The $232 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $47K · 2020: $12K · 2021: $7,008 · 2022: $11K · 2023: $662 · 2024: $405 · 2025: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $300 · Education: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $828.21 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $300.00 |
| Education | $170.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $40,363.92 | 2019-2023 | Xarelto |
| Glaxosmithkline, LLC. | $35,100.06 | 2019-2025 | Arexvy, Nucala |
| Viiv Healthcare Company | $600.00 | 2019 | |
| Intuitive Surgical, INC. | $257.57 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $228.68 | 2023-2024 | Ofev |
| Chiesi USA, INC. | $188.60 | 2025 | |
| Exthera Medical Corporation | $180.09 | 2023 | |
| Mylan Specialty L.P. | $179.45 | 2022 | |
| Monaghan Medical Corporation | $150.00 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $149.89 | 2024 | Uptravi |
| Astrazeneca Pharmaceuticals LP | $125.01 | 2020 | |
| Novo Nordisk INC | $116.56 | 2019 | |
| Circassia INC. | $102.71 | 2019 | |
| 4dmedical USA INC | $94.00 | 2024 | Ct Lvas |
| Grifols Shared Services North America, INC. | $21.39 | 2025 | Prolastin-C Liquid |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.